Benzinga · Oct 8, 2026
RBC Capital Maintains Outperform on BeOne Medicines, Raises Price Target to $459
RBC Capital analyst Leonid Timashev maintains BeOne Medicines (NASDAQ:ONC) with a Outperform and raises the price target from $450 to $459.
ON
NASDAQ · ONC
BeOne Medicines Ltd.
Healthcare · Medical - Pharmaceuticals
$354.47
Up+$4.34 (+1.24%)
Updated Oct 12, 2026, 2:50 AM
SID Score
6.0/10
Composite research score
Smart Money
56/100
Neutral
- Market cap
- 34.25B
- P/E ratio
- -21.14
- Dividend yield
- 0.00%
- 52-week range
- $253.95 – $385.22
- Volume
- 318.33K
- Avg. volume
- 259.1K
Price performance · ONC
ONC price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 9, 2026
ONC closed at $354.47 after 20 trading sessions, up 0.18% for the selected period.
- Last close
- $354.47
- Period change
- +0.18%
- Period low
- $346.50
- Period high
- $368.08
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 9, 2026 | $348.00 | $357.14 | $347.72 | $354.47 | 318.33K |
| Oct 8, 2026 | $351.94 | $355.01 | $340.445 | $350.13 | 418.69K |
| Oct 7, 2026 | $360.01 | $367.57 | $359.4075 | $364.02 | 148.64K |
| Oct 6, 2026 | $365.13 | $368.40 | $359.10 | $362.78 | 319.92K |
| Oct 5, 2026 | $362.48 | $362.83 | $356.82 | $361.65 | 392.12K |
| Oct 2, 2026 | $351.01 | $358.57 | $349.74 | $358.07 | 505.17K |
| Oct 1, 2026 | $367.94 | $371.09 | $358.32 | $358.77 | 351.45K |
| Sep 30, 2026 | $370.00 | $376.50 | $365.79 | $365.94 | 328.88K |
| Sep 29, 2026 | $362.76 | $367.43 | $357.17 | $365.27 | 372.8K |
| Sep 28, 2026 | $360.42 | $368.0512 | $358.00 | $367.00 | 350.55K |
| Sep 25, 2026 | $362.51 | $365.00 | $358.51 | $360.85 | 377.18K |
| Sep 24, 2026 | $355.37 | $361.12 | $354.94 | $359.97 | 472.85K |
| Sep 23, 2026 | $362.50 | $365.70 | $361.31 | $365.00 | 631.81K |
| Sep 22, 2026 | $364.95 | $368.28 | $359.82 | $368.08 | 262.93K |
| Sep 21, 2026 | $360.42 | $366.9999 | $358.24 | $365.67 | 488.98K |
| Sep 18, 2026 | $352.13 | $354.045 | $348.76 | $350.84 | 438.38K |
| Sep 17, 2026 | $351.41 | $354.608 | $351.05 | $353.46 | 286K |
| Sep 16, 2026 | $342.88 | $349.57 | $342.88 | $348.08 | 356.7K |
| Sep 15, 2026 | $353.55 | $354.50 | $345.80 | $346.50 | 257.3K |
| Sep 14, 2026 | $354.44 | $356.00 | $351.915 | $353.83 | 251.18K |
Latest ONC news
The latest Smart Investors Daily articles mentioning ONC.
Stock researchCompany · Overview
Company
Market Activity
Research & News
ONC research
Overview
Company profile and research snapshot.
Company profile
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $397.00
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
Benzinga · Oct 7, 2026
Truist Securities Maintains Buy on BeOne Medicines, Raises Price Target to $420
Truist Securities analyst Gregory Renza maintains BeOne Medicines (NASDAQ:ONC) with a Buy and raises the price target from $418 to $420.
Yahoo · Oct 1, 2026
Biotech Leader BeOne Medicines Poised To Hit Early Buy Points
Biotech leader BeOne stock is poised to hit multiple buy points. Its blockbuster drug generated $1.2 billion in sales in the second quarter.
Benzinga · Oct 1, 2026
JP Morgan Maintains Overweight on BeOne Medicines, Raises Price Target to $445
JP Morgan analyst Jessica Fye maintains BeOne Medicines (NASDAQ:ONC) with a Overweight and raises the price target from $425 to $445.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
